GERN - Geron Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.59
0.00 (0.00%)
At close: 4:00PM EDT

3.59 0.00 (0.00%)
After hours: 4:16PM EDT

Stock chart is not supported by your current browser
Previous Close3.59
Open3.57
Bid3.52 x 1100
Ask3.59 x 1100
Day's Range3.43 - 3.63
52 Week Range1.74 - 6.68
Volume2,968,045
Avg. Volume4,492,265
Market Cap621.361M
Beta2.53
PE Ratio (TTM)N/A
EPS (TTM)-0.18
Earnings DateMay 4, 2017 - May 8, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.75
Trade prices are not sourced from all markets
  • MARKETS: Here's why stocks are dropping right now
    Yahoo Finance Videolast month

    MARKETS: Here's why stocks are dropping right now

    Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after the Trump administration released details on the latest round of China tariffs, to which China has responded in kind. In other news, the June Empire State Manufacturing Survey beat Wall Street expectations on nearly every front.

  • MARKETS: Here's why stocks are surging and how it could all go wrong
    Yahoo Finance Video2 months ago

    MARKETS: Here's why stocks are surging and how it could all go wrong

    Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.

  • Reutersyesterday

    BRIEF-Geron's Unit To Invest 283.0 Mln Yuan In Stainless Steel Plate Project

    July 17 (Reuters) - Geron Co Ltd: * SAYS UNIT TO INVEST 283.0 MILLION YUAN ($42.35 million) IN STAINLESS STEEL PLATE PROJECT Source text in Chinese: https://bit.ly/2uGwvZt Further company coverage: ($1 ...

  • Are Options Traders Betting on a Big Move in Geron (GERN) Stock?
    Zacks5 days ago

    Are Options Traders Betting on a Big Move in Geron (GERN) Stock?

    Investors in Geron (GERN) need to pay close attention to the stock based on moves in the options market lately.

  • ACCESSWIRE10 days ago

    These Biotech Companies are a Treat for Investors

    HENDERSON, NV / ACCESSWIRE / July 8, 2018 / In order to take a drug to market the cost was estimated to be $2.4 billion. This has caused many biotech firms to enter the device market, rather than drug ...

  • Why Geron Corp. Stock Has Skyrocketed 90.6% in 2018 (So Far)
    Motley Fool12 days ago

    Why Geron Corp. Stock Has Skyrocketed 90.6% in 2018 (So Far)

    A key decision on its only drug in development is on tap.

  • ACCESSWIRE16 days ago

    Today's Research Reports on Trending Tickers: Geron and Celgene

    NEW YORK, NY / ACCESSWIRE / July 2, 2018 / Major U.S. markets finished higher on Friday, but finished the week lower due to ongoing global trade concerns. The Dow Jones Industrial Average increased 0.23 ...

  • Understanding Geron Corp’s IMerge Trial
    Market Realist28 days ago

    Understanding Geron Corp’s IMerge Trial

    IMerge, a two-part clinical trial, is evaluating Geron’s (GERN) imetelstat in transfusion-dependent patients with low- or intermediate-risk myelodysplastic syndromes who have relapsed after or are refractory to prior treatment with an erythropoiesis-stimulating agent. Its primary efficacy endpoint is planned to be the rate of RBC-TI (red blood cell transfusion independence) for at least eight weeks. Key secondary endpoints are to be RBC-TI rates for 24 weeks, the amount of and changes in red blood cell transfusions, and hematologic improvement.

  • Understanding Geron’s Cash Flow and Bottom Line
    Market Realist28 days ago

    Understanding Geron’s Cash Flow and Bottom Line

    Its interest expenses fell YoY (year-over-year) to $18,000 from $21,000, and its net loss was stable YoY, growing slightly to ~$7.19 million from $7.18 million. Its net loss per share improved YoY, shrinking to $0.04 from $0.05. In Q1 2018, Geron’s cash outflow from operating activities rose YoY to $7.37 million from $7.31 million. Its current ratio, which measures how effectively it can meet its short-term obligations, improved YoY to 20.8 from 9.

  • Insights into Geron’s Collaboration with Janssen Biotech
    Market Realist28 days ago

    Insights into Geron’s Collaboration with Janssen Biotech

    In August 2015, Geron (GERN) entered into a market issuance sales agreement with MLV, under which Geron could issue and sell its common stock for up to $50 million. Under the agreement, in Q1 2018, Geron sold ~776,800 shares of its common stock for net proceeds of ~$1.6 million. Geron entered into a collaboration and licensing agreement with Janssen Biotech in November 2014.

  • A Look at Geron’s Imetelstat Research Program
    Market Realist28 days ago

    A Look at Geron’s Imetelstat Research Program

    IMbark, a Phase 2 clinical trial, is evaluating two dose levels of Geron’s (GERN) imetelstat in ~200 myelofibrosis patients who have relapsed after or are refractory to prior treatment with a janus kinase inhibitor. The primary endpoints for the trial are the spleen and symptom response rates. The secondary endpoints of the trial include safety and overall survival. Geron expects an overall survival assessment to provide key information for the imetelstat program for potential future clinical trials. The drug’s safety profile was found to be consistent with prior clinical trials focusing on hematologic malignancies.

  • Analysts’ Ratings for Geron and Peers
    Market Realist28 days ago

    Analysts’ Ratings for Geron and Peers

    In collaboration with Janssen Biotech, biopharmaceutical company Geron (GERN) is currently supporting the clinical development of imetelstat for hematologic myeloid malignancies. Early clinical data for the drug suggests it may have disease-modifying activity by inhibiting progenitor cells of malignant clones for myelofibrosis, myelodysplastic syndromes, and essential thrombocythemia. The sole analyst covering Geron recommends “hold.” In April, there were three analysts covering the stock, of which one recommended “buy,” and two recommended “hold.” Their target price was $5.50.

  • Analyzing Geron’s Financial Performance
    Market Realist28 days ago

    Analyzing Geron’s Financial Performance

    In Q1 2018, Geron’s (GERN) license fee and royalty revenue fell YoY (year-over-year) to $318,000 from $537,000, with license fee revenue falling YoY to $248,000 from $409,000. This decrease was due to a reduction in its number of active agreements for research licenses related to its human telomerase reverse transcriptase technology.

  • Why Geron Corporation Stock Is Heading Higher Today
    Motley Foollast month

    Why Geron Corporation Stock Is Heading Higher Today

    The company's EHA conference over the weekend has investors snapping up shares today.

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: Geron Corporation and BioMarin Pharmaceutical

    NEW YORK, NY / ACCESSWIRE / June 18, 2018 / Biotech stocks Geron Corporation and BioMarin Pharmaceutical were both rising in Friday’s trading session with gains of almost 10% by the close of the day. While Geron had no significant news, BioMarin announced last week that it has dosed its first participant in a global phase II study for vosoritide, an experimental drug for the treatment of achondroplasia.

  • GlobeNewswirelast month

    Geron Reports Imetelstat Oral Presentation at European Hematology Association Congress

    Geron Corporation (GERN) today announced the oral presentation of updated data from the ongoing original Part 1 of IMerge, the Phase 2/3 trial of imetelstat in lower risk myelodysplastic syndromes (MDS). The data was presented by Dr. David Steensma from the Dana-Farber Cancer Institute at the 23rd Congress of the European Hematology Association (EHA) held in Stockholm, Sweden on June 17. Imetelstat is a telomerase inhibitor initially developed by Geron and exclusively licensed to Janssen Biotech, Inc. (Janssen) on a worldwide basis.

  • ACCESSWIRElast month

    Free Technical Reports on Gilead Sciences and Three Additional Biotech Equities

    On Wednesday, June 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Wednesday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Geron Corp. (NASDAQ: GERN), Gilead Sciences Inc. (NASDAQ: GILD), Global Blood Therapeutics Inc. (NASDAQ: GBT), and GlycoMimetics Inc. (NASDAQ: GLYC).

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Loxo Oncology and Geron Corporation

    NEW YORK, NY / ACCESSWIRE / June 11, 2018 / U.S. markets finished higher and logged strongest week in months as investors shrug off tensions between U.S. and its allies. The Dow Jones Industrial Average ...

  • These 3 Stocks Shot Up 50% in 2017 -- Are They Still Buys?
    Motley Fool2 months ago

    These 3 Stocks Shot Up 50% in 2017 -- Are They Still Buys?

    Why an airplane giant, a drugmaker, and an alcoholic beverage specialist could each see more market-thumping gains ahead.

  • 3 Likely Reasons Geron Stock Is Sizzling Hot Right Now
    Motley Fool2 months ago

    3 Likely Reasons Geron Stock Is Sizzling Hot Right Now

    This biotech stock is skyrocketing. Here's why -- maybe.

  • What Is Geron Corporation's Downside Risk?
    Motley Fool2 months ago

    What Is Geron Corporation's Downside Risk?

    Management's bold moves have been steadily stemming concerns about the company's future.

  • Why Geron Corporation Stock Is Heating Up
    Motley Fool2 months ago

    Why Geron Corporation Stock Is Heating Up

    Geron's stock is blasting higher this week, but the exact reason isn't clear.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Geron and Forward Pharma

    NEW YORK, NY / ACCESSWIRE / May 23, 2018 / U.S. markets fell Tuesday on geopolitical concerns after President Trump stated he was not happy with the current U.S. – China trade talks. The Dow Jones Industrial ...

  • GlobeNewswire2 months ago

    Geron Announces Oral Presentation at European Hematology Association Congress

    Geron Corporation (GERN) today announced that an abstract describing clinical data regarding the telomerase inhibitor imetelstat has been selected for an oral presentation at the 23rd Congress of the European Hematology Association (EHA) to be held in Stockholm, Sweden from June 14-17, 2018. The abstract contains updated data (as of January 2018) from the first 32 patients enrolled in Part 1 of IMerge, the ongoing Phase 2/3 clinical trial of imetelstat in patients with lower risk myelodysplastic syndromes (MDS) being conducted by Janssen Research & Development, LLC.

  • A Huge Decision Is on Tap for This Little Biotech Stock
    Motley Fool2 months ago

    A Huge Decision Is on Tap for This Little Biotech Stock

    A make-it or break-it determination is fast approaching for one tiny clinical-stage company.